Evolution of FDA Cybersecurity Requirements

FDA cybersecurity requirements evolved in four phases: voluntary premarket guidance in 2014, postmarket guidance in 2016, the legally binding Section 524B of the FD&C Act enacted in December 2022, and the current premarket guidance built around the Secure Product Development Framework. Each phase widened the scope and raised the bar for what submissions must contain.

2.3.1 Phase 1: Initial Guidance (2014)

Document: "Content of Premarket Submissions for Management of Cybersecurity in Medical Devices"

The FDA's first cybersecurity guidance, finalized in October 2014, marked a turning point (the agency's cybersecurity guidance documents are collected on the FDA medical device cybersecurity page). For the first time, FDA provided specific recommendations for addressing cybersecurity during device design. Key elements included:

• Risk-based approach: Focus efforts based on potential patient harm
• Design controls: Integrate security into existing quality system processes
• Documentation expectations: What to include in premarket submissions
• Security controls: Authentication, encryption, software updates, etc.

However, this guidance had limitations:

• It was voluntary (recommendations, not requirements)
• It focused only on premarket considerations
• Post-market cybersecurity wasn't addressed
• Many manufacturers implemented it inconsistently

2.3.2 Phase 2: Post-Market Guidance (2016)

Document: "Postmarket Management of Cybersecurity in Medical Devices"

The 2016 post-market guidance filled a critical gap. FDA recognized that cybersecurity isn't just a design issue - it requires ongoing attention throughout the device lifecycle. This guidance introduced several important concepts:

Component Transparency and Vulnerability Management:

• Understand and document software components in devices
• Monitor for newly discovered vulnerabilities
• Maintain processes to assess and address vulnerabilities
• Track software versions and updates

Coordinated Vulnerability Disclosure:

• Work with security researchers
• Establish reporting channels
• Respond to vulnerabilities promptly

Risk-Based Approach to Remediation:

• Controlled risks: Regular update cycles acceptable
• Uncontrolled risks: Immediate action required

Information Sharing:

• Participate in ISAOs (Information Sharing and Analysis Organizations)
• Share threat intelligence
• Learn from others' experiences

2.3.3 Phase 3: Legislative Action (2022)

The Game Changer: Section 3305 of the Consolidated Appropriations Act, 2023

On December 29, 2022, everything changed. Congress added Section 524B to the Food, Drug, and Cosmetic Act, making certain cybersecurity requirements legally mandatory for the first time. The requirements took effect for submissions on March 29, 2023, and starting October 1, 2023 FDA could refuse to accept premarket submissions for cyber devices that lack the required cybersecurity information.

According to the FDA's 2023 guidance (and its 2025 update): "Section 524B(c) of the FD&C Act defines 'cyber device' as a device that:

1. includes software validated, installed, or authorized by the sponsor as a device or in a device;
2. has the ability to connect to the internet; and
3. contains any such technological characteristics validated, installed, or authorized by the sponsor that could be vulnerable to cybersecurity threats."

What Section 524B Requires

For "cyber devices," manufacturers MUST submit:

1. Cybersecurity Management Plan including:

   • Monitoring processes for vulnerabilities
   • Procedures for addressing vulnerabilities
   • Timeline for security updates
   • Communication plans

2. Software Bill of Materials (SBOM) containing:

   • Commercial software components
   • Open-source software components
   • Known vulnerabilities

3. Evidence of Security Controls demonstrating:

   • Secure design practices
   • Security testing results
   • Update capabilities

These aren't suggestions - they're legal requirements with potential enforcement actions for non-compliance.

2.3.4 Phase 4: Current Framework (2025)

Document: "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions"

The 2025 guidance, updated from its original 2023 release, represents FDA's current thinking and incorporates lessons learned since 2014. Major updates include:

Broader Scope: According to the guidance: "This guidance document is applicable to devices with cybersecurity considerations, including but not limited to devices that have a device software function or that contain software (including firmware) or programmable logic. The guidance is not limited to devices that are network-enabled or contain other connected capabilities."

Secure Product Development Framework (SPDF): The guidance introduces SPDF as "a set of processes that reduce the number and severity of vulnerabilities in products throughout the device lifecycle."

Enhanced Documentation Requirements:

• Security architecture views
• Threat models
• SBOM with vulnerability assessment
• Security risk management documentation

Quality System Integration: Clear connection between cybersecurity and existing quality system requirements under 21 CFR Part 820.

For what changed when the QMSR replaced the QSR in 2026, see FDA's 3rd cybersecurity guidance in 3 years: what actually changed?.